Statement re share price, update on EpiSwitch PSE

Summary by AI BETAClose X

Oxford BioDynamics Plc has issued a statement addressing recent share price movements, clarifying that the UK National Screening Committee's draft recommendation on prostate cancer screening has no direct impact on the company or its EpiSwitch PSE test. The company highlighted that sales of its PSE test in the US and to private healthcare in the UK have shown consistent growth, with six consecutive record months reported from June to November 2025, indicating ongoing commercial success.

Disclaimer*

UK 100

Latest directors dealings